Quarterly ResultAug 12, 2026, 04:15 PM
ABVC BioPharma Reports Q2 Net Loss $810K; Going Concern Doubt
AI Summary
ABVC BioPharma reported a net loss of $810,481 for the second quarter of 2026 and $2,500,418 for the first half of 2026. The company's cash and cash equivalents significantly decreased to $31,944, and it faces a working capital deficit of $5,282,776, raising substantial doubt about its ability to continue as a going concern. Additionally, the planned distribution of BioKey Cayman shares to ABVC shareholders has been postponed due to outstanding tax, administrative, and regulatory matters.
Key Highlights
- Net loss for Q2 2026 was $810,481, compared to $2,332,833 for Q2 2025.
- Net loss for H1 2026 was $2,500,418, compared to $3,277,023 for H1 2025.
- Cash and cash equivalents decreased to $31,944 as of June 30, 2026, from $681,480 at Dec 31, 2025.
- Working capital deficit was $5,282,776 as of June 30, 2026.
- Net cash used in operating activities for H1 2026 was $1,138,656.
- Total assets decreased to $19,400,715 as of June 30, 2026, from $21,062,203 at Dec 31, 2025.
- Total stockholders' equity decreased to $10,287,183 as of June 30, 2026, from $11,111,861 at Dec 31, 2025.
- BioKey Cayman distribution of 15% shares to ABVC shareholders was postponed from August 3, 2026.
Price Impact
More from ABVC